2021-10-28| Asia-PacificCOVID-19

South Korea Approves EUA for Moderna’s COVID-19 Vaccine Produced by Samsung Biologics

by Kathy Huang
Share To

On October 26, South Korea’s health ministry granted emergency use approval (EUA) for Moderna’s Covid-19 vaccine produced by Samsung Biologics. 

The approval was timely as the South Korean pharma giant only obtained Good Manufacturing Practice (GMP) certification earlier this week.


Deal with Moderna this May

In May, US President Joe Biden and his South Korean counterpart Moon Jae-In agreed to partner on COVID-19 vaccines between two countries. 

Following the discussion, Moderna and Samsung Biologics signed on a contract production deal, under which the latter will provide fill-finish manufacturing for Moderna’s COVID-19 vaccine, mRNA-1273.

Production of the vaccines began in August, during which Samsung Biologics waited for its third plant in Songdo to secure enough volume for the manufacturing service. The plant is awaiting approval from US and EU regulators to ship vaccines outside the country, said the company.

According to Korea’s health ministry, the Moderna vaccines manufactured by Samsung Biologics will be released by the end of this year, to be administered as booster shots for high-risk populations.


South Korea’s Second CMO Deal with COVID-19 Vaccine Developers

Samsung Biologics is the second Korean pharma to produce COVID-19 vaccine via contract manufacturing with global COVID-19 vaccine developers.

In 2020 July, SK Bioscience inked a contract with AstraZeneca to manufacture the COVID-19 vaccine in Korea domestically. According to official statistics, 72% of the Korean population has been fully vaccinated, and about 78.8% has received the first COVID-19 vaccine shot.

© All rights reserved. Collaborate with us:
Related Post
The COVID-19 Pandemic: Is Omicron the Last Variant?
FDA Approves Both Moderna’s and Pfizer/BioNTech’s Omicron Bivalent Vaccines in One Day
AstraZeneca’s Role in COVID-19 Slows Down as World Looks to mRNA Vaccines
AstraZeneca Welcomes Neurofibromatosis And Asthma Treatment Approvals in Japan
Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial
Arsenal Biosciences Announced Another $70 million Collaboration, This Time With Genentech
Sciwind Biosciences And SynerK Join Forces To Develop siRNA Therapeutics
Acticor Enrolls First Patient in Phase 2/3 Stroke Treatment Study
Daiichi Sankyo Wins Approval For Cancer Treatment in Japan
Seagen Strikes Potential $650 million Deal with LAVA Therapeutics for Cancer Treatment
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!